Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...

Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third ...

Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to ...

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

17 news release by the university. The drug, guselkumab, marketed under the brand name Tremfya, was approved Sept. 11, according to the release. The first dose was administered Sept. 17 to a ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

Johnson & Johnson has announced that the US FDA has approved TREMFYA for the treatment of active ulcerative colitis (UC).

Johnson & Johnson already has a major presence in the crowded inflammatory bowel disease (IBD) space with its popular Stelara ...

Johnson & Johnson (JNJ) gains FDA approval to expand the labeling for its monoclonal antibody Tremfya for ulcerative colitis.

Johnson & Johnson (JNJ) said that the U.S. Food and Drug Administration has approved TREMFYA (guselkumab) for the treatment of adults ...